Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 14/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704252 | 0.91 | BDKRB1 (0.64) | BDKRB1CHRM4 | |
| SCHEMBL4700959 | 0.89 | BDKRB1 (0.57) | BDKRB1F10CHRM4 | |
| SCHEMBL4700707 | 0.88 | BDKRB1 (0.57) | BDKRB1F10CHRM4 | |
| SCHEMBL6046023 | 0.88 | BDKRB1 (0.71) | BDKRB1 | |
| SCHEMBL4702570 | 0.88 | BDKRB1 (0.65) | BDKRB1MEN1KMT2A | |
| SCHEMBL4700946 | 0.87 | BDKRB1 (0.57) | BDKRB1MEN1KMT2ACHRM4 | |
| SCHEMBL4706708 | 0.86 | BDKRB1 (0.55) | BDKRB1F10KMT2ACHRM4 | |
| SCHEMBL4706219 | 0.84 | BDKRB1 (0.70) | BDKRB1F10MEN1KMT2ACHRM4 | |
| SCHEMBL4704818 | 0.84 | BDKRB1 (0.79) | BDKRB1F10MEN1KMT2ACHRM4 | |
| SCHEMBL6046111 | 0.79 | BDKRB1 (0.84) | BDKRB1MEN1KMT2ACHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |